Advertisement

Topics

Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients: a systematic review.

07:00 EST 1st January 2017 | BioPortfolio

Summary of "Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients: a systematic review."

Clostridium difficile bacteria are a leading cause of infectious diarrhea. This is an anaerobic, gram-positive and spore-forming rod responsible for significant morbidity and mortality, especially among elderly hospitalized patients. Standard management of C. difficile-associated diarrhea (CDAD) consists of discontinuing a causative antibiotic, correcting fluid-electrolytes imbalance and initiating an antibiotic treatment for CDAD. Alternative approaches for prevention of CDAD include probiotics. This systematic review will provide a comprehensive, unbiased summary of the available research on the effectiveness of probiotics in decreasing the incidence of infectious diarrhea in elderly hospitalized patients.

Affiliation

Journal Details

This article was published in the following journal.

Name: JBI database of systematic reviews and implementation reports
ISSN: 2202-4433
Pages: 140-164

Links

DeepDyve research library

PubMed Articles [7257 Associated PubMed Articles listed on BioPortfolio]

A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO).

Clostridium difficile is the most common cause of hospital-acquired infections, responsible for >450 000 infections annually in the USA. Probiotics provide a promising, well-tolerated adjunct therap...

Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.

Fidaxomicin is an approved therapy for Clostridium difficile-associated diarrhea (CDAD) in adults. The safety of fidaxomicin in children has not been reported.

Carvacrol reduces Clostridium difficile sporulation and spore outgrowth in vitro.

Clostridium difficile is an anaerobic spore-forming pathogen that causes a serious toxin-mediated enteric disease in humans. Therapeutic agents that are capable of reducing C. difficile spore producti...

Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.

Diarrhea caused by Clostridium difficile is one of the major emerging threats to modern healthcare systems worldwide. Although C. difficile spores are present in the gut innocuously, because of repeat...

IL-27/IL-27receptor signaling provides protection in Clostridium difficile-induced colitis.

Clostridium difficile is a leading cause of nosocomial infection. The role of cytokine IL-27 in the immunopathology of Clostridium difficile infection (CDI) remains unknown.

Clinical Trials [3891 Associated Clinical Trials listed on BioPortfolio]

Probiotics in the Reduction of Antibiotic Associated Diarrhea

The study will evaluate the effectiveness of probiotic therapy in reducing the incidence of antibiotic associated diarrhea (AAD) and Clostridium difficile associated diarrhea (CDAD) in pne...

Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir

This study is being conducted to investigate the potential benefits of probiotic intake for preventing antibiotic associated diarrhea and Clostridium difficile infection in patients underg...

Immune Response to FMT for C.Difficile

The protocol aims to address the basic mechanisms of Clostridium difficile pathogenesis by identifying how Clostridium difficile toxins inhibit eosinophils that otherwise would protect the...

Clostridium Difficile Vaccine Efficacy Trial (Clover)

The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are ...

Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients

Symptoms of Clostridium difficile infection is almost always induced as a complication to the use of antibiotics. Most ICU patients are given antibiotics. Probiotics has the ability to i...

Medical and Biotech [MESH] Definitions

Type species of the genus CLOSTRIDIUM, a gram-positive bacteria in the family Clostridiaceae. It is used as a source of PROBIOTICS.

A common inhabitant of the colon flora in human infants and sometimes in adults. It produces a toxin that causes pseudomembranous enterocolitis (ENTEROCOLITIS, PSEUDOMEMBRANOUS) in patients receiving antibiotic therapy.

An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.

A species of Saccharomyces that is used as a PROBIOTIC, such as in the treatment of DIARRHEA and PSEUDOMEMBRANOUS ENTEROCOLITIS associated with CLOSTRIDIUM INFECTIONS.

Live microbial DIETARY SUPPLEMENTS which beneficially affect the host animal by improving its intestinal microbial balance. Antibiotics and other related compounds are not included in this definition. In humans, lactobacilli are commonly used as probiotics, either as single species or in mixed culture with other bacteria. Other genera that have been used are bifidobacteria and streptococci. (J. Nutr. 1995;125:1401-12)

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topics

Clostridium difficile (CDI)
A clostridium difficile infection (CDI) is a type of bacterial infection that can affect the digestive system. It most commonly affects people who are staying in hospital.  The symptoms of CDI can range from mild to severe and include: diarrhoe...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Article